CANF
Can-Fite BioPharma Ltd.
There isn't enough reported data to score CANF yet.
CANF Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CANF's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
CANF PE Valuation
CANF has no meaningful PE right now: it lost money over the past year.
CANF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CANF's revenue to decline, with its earnings and profitability holding steady.
CANF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2023 | -$2.00 | +$2.00 |
| Q4 2022 | -$2.00 | +$4.00 |
| Q2 2022 | -$4.00 | -$2.00 |
| Q4 2021 | -$6.00 | +$2.00 |
| Q4 2020 | -$8.00 | +$14.00 |
| Q4 2019 | -$22.00 | -104% |
| Q4 2018 | $510.00 | -11% |
CANF is still losing money, but far less than before: $0.00 per share over the past year, against $22.00 at its worst in late 2019.
CANF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $203K | -43% |
| Q2 2025 | $202K | -36% |
| Q4 2024 | $358K | +2% |
| Q2 2024 | $316K | -19% |
| Q4 2023 | $351K | -12% |
| Q2 2023 | $392K | -4.2% |
| Q4 2022 | $401K | -12% |
| Q2 2022 | $409K | +2.8% |
CANF's revenue has slid since its 2018 peak: $203,000 last quarter, down 42% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -2489% | -1435 points |
| Q2 2025 | -2425% | -1278 points |
| Q4 2024 | -1127% | +283 points |
| Q2 2024 | -1296% | -210 points |
| Q4 2023 | -1054% | +603 points |
| Q2 2023 | -1147% | +186 points |
| Q4 2022 | -1410% | +260 points |
| Q2 2022 | -1086% | +931 points |
CANF's operating margin was −2489% last quarter, down 1435 points from the same quarter a year ago, near the bottom of its range since 2017.
CANF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$4.2M | -$596K |
| Q2 2025 | -$4.8M | -$713K |
| Q4 2024 | -$3.6M | -$207K |
| Q2 2024 | -$4M | +$1M |
| Q4 2023 | -$3.4M | +$1.3M |
| Q2 2023 | -$5M | +$1M |
| Q4 2022 | -$4.7M | +$1.7M |
| Q2 2022 | -$6.1M | -$2.6M |
CANF has burned cash in almost every quarter: −$17M over the past year, against −$19M the year before.
CANF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +87% | +79.5M shares |
| 1 year | +4083% | +167M shares |
CANF has 171M diluted shares, up 4083% from a year ago.
CANF Net Leverage
CANF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CANF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.8 | Oversold |
| Stochastic | 2.7 | Oversold |
CANF's weekly RSI is 27 (oversold) and its Stochastic is 3 (oversold).
CANF PE vs Healthcare Sector
CANF has no meaningful PE right now: it lost money over the past year.
CANF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.81 | 18% below |
| 20 week MA | $2.59 | 42% below |
| 50 week MA | $3.33 | 55% below |
| 100 week MA | $12.2 | 88% below |
| 200 week MA | $30.8 | 95% below |
CANF is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
CANF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $690.0 | $370.0 | -46% |
| 2021 | $370.0 | $274.0 | -26% |
| 2022 | $274.0 | $128.0 | -53% |
| 2023 | $128.0 | $44.0 | -66% |
| 2024 | $44.0 | $31.6 | -28% |
| 2025 | $31.6 | $4.28 | -86% |
| 2026 YTD | $4.28 | $1.49 | -65% |
CANF has finished every year since 2020 lower, and it's down 65% so far in 2026.